About us

Founded in September 2005 by Dr Roger LAHANA, CEO, and Karine LARBOURET, Director of Operations, Neorphys is a company which discovers and develops novel, proprietary analgesic drug candidates with low side effects, especially with regard to gastro-intestinal transit. This is why the most advanced drug candidate is developed for visceral pain management.

Beside the co-founders, Neorphys scientists, all PhD’s or equivalent, share a strong expertise in opioids and acute pain as well as in behavioural pharmacology. They have a proven track record of success in using discovery techniques such as medicinal chemistry, cell biology, toxicology and relevant animal assays.

Business model

Neorphys discovers, optimises and develops novel analgesic drug candidates up to Phase 2b, then intends to licence out the most promising compounds to pharmaceutical companies.

Neorphys is also considering partnerships with pharmaceutical companies to co-develop some in-house drug candidates.

For more details, contact us directly: